4.7 Article

Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study

期刊

CLINICAL MICROBIOLOGY AND INFECTION
卷 27, 期 1, 页码 83-88

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.cmi.2020.07.041

关键词

Co-infections; COVID-19; Mortality; SARS-CoV-2; Superinfections

资金

  1. AGAUR of the Catalan Health Agency [2017SGR1432]
  2. EIT Health
  3. European Institute of Innovation and Technology (EIT)
  4. European Union
  5. European Regional Development Fund (EDRD)
  6. Ministerio de Sanidad y Consumo, Instituto de Salud Carlos III [PI18/01061, CM18/00132, FI19/00133, FIS PI18/01061]

向作者/读者索取更多资源

The study found that co-infections and superinfections in hospitalized COVID-19 patients were relatively low compared to other viral pandemics. Patients experienced worse outcomes after hospital-acquired superinfections occurred.
Objectives: To describe the burden, epidemiology and outcomes of co-infections and superinfections occurring in hospitalized patients with coronavirus disease 2019 (COVID-19). Methods: We performed an observational cohort study of all consecutive patients admitted for >= 48 hours to the Hospital Clinic of Barcelona for COVID-19 (28 February to 22 April 2020) who were discharged or dead. We describe demographic, epidemiologic, laboratory and microbiologic results, as well as outcome data retrieved from electronic health records. Results: Of a total of 989 consecutive patients with COVID-19, 72 (7.2%) had 88 other microbiologically confirmed infections: 74 were bacterial, seven fungal and seven viral. Community-acquired co-infection at COVID-19 diagnosis was uncommon (31/989, 3.1%) and mainly caused by Streptococcus pneumoniae and Staphylococcus aureus. A total of 51 hospital-acquired bacterial superinfections, mostly caused by Pseudomonas aeruginosa and Escherichia coli, were diagnosed in 43 patients (4.7%), with a mean (SD) time from hospital admission to superinfection diagnosis of 10.6 (6.6) days. Overall mortality was 9.8% (97/989). Patients with community-acquired co-infections and hospital-acquired superinfections had worse outcomes. Conclusions: Co-infection at COVID-19 diagnosis is uncommon. Few patients developed superinfections during hospitalization. These findings are different compared to those of other viral pandemics. As it relates to hospitalized patients with COVID-19, such findings could prove essential in defining the role of empiric antimicrobial therapy or stewardship strategies. (C) 2020 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据